Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Conditions

• Type 2 Diabetic Nephropathy

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Dulaglutide Injection — DRUG
  Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.

Study Details

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.

Key Dates

Start date

Oct 30, 2021

Status verified

Dec 2023

Primary completion

Jun 30, 2023

Completion

Oct 30, 2023

Study Design

Enrollment

300 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Dulaglutide
  Dulaglutide was injected subcutaneously at standard dose and frequency for consecutive 12 months.
• Active Comparator: other hypoglycemic agents not including GLP-1 receptor agonists
  Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.

Primary Outcome Measure

Evaluation of the urinary albumin-to-creatinine ratio [ Time Frame: 3,6 and 12 months after dulaglutide injection treatment ]